natgillin/translations-raw huggingface dataset:
If considered necessary the doctor may prescribe a second dose of 9.1 mg after two hours. 
Po potrebi lahko zdravnik po dveh urah predpiše drugi 9,1-miligramski odmerek.
Loxapine works mainly by blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine. 
Loksapin večinoma blokira receptorje za nevrotransmiterje 5hidroksitriptamina (imenovanega tudi serotonin) in dopamin.
What benefit has Adasuve shown during the studies? 
Kakšne koristi je zdravilo Adasuve izkazalo med študijami?
Schizophrenia is a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). 
Shizofrenija je duševna bolezen, ki ima vrsto simptomov, vključno z neorganiziranim mišljenjem in govorom, halucinacijami (bolnik vidi ali sliši stvari, ki jih ni), sumničavostjo ter blodnjami (zmotnimi prepričanji).
The CHMP concluded that the benefits of Adasuve outweigh its risks and recommended that it be granted marketing authorisation. 
Odbor CHMP je zaključil, da so koristi zdravila Adasuve večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Bipolar disorder is a mental illness with alternating periods of high mood and depression. 
Bipolarna motnja je duševna bolezen, pri kateri se izmenjujejo obdobja privzdignjenega razpoloženja in depresije.
It is available as an inhalation powder in a portable inhaler device for single use (4.5 mg and 9.1 mg). 
Na voljo je v obliki praška za inhaliranje v prenosnem inhalatorju za enkratno uporabo (4,5 mg in 9,1 mg).
The main measure of effectiveness was the change in the patients' symptoms two hours after giving a dose of loxapine, assessed using a standard scale of agitation in patients with schizophrenia and bipolar disorder (positive and negative symptom scale, excited component: PEC score). 
Glavno merilo učinkovitosti je bila sprememba bolnikovih simptomov dve uri po dajanju odmerka loksapina, ki so jo ocenili na podlagi standardne ocenjevalne lestvice agitacije pri bolnikih s shizofrenijo in bipolarno motnjo (lestvica pozitivnih in negativnih simptomov, komponenta razburjenosti: rezultat PEC).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adasuve. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Adasuve, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It must also not be used in patients with symptoms such as wheezing and shortness of breath or who have lung conditions such as asthma or chronic obstructive pulmonary disease. 
Zdravilo se prav tako ne sme uporabljati pri bolniki s simptomi, kot so sopenje in kratka sapa, ali pri bolnikih s težavami s pljuči, kot so astma ali kronična obstruktivna pljučna bolezen.
Treatment with Adasuve is started with the inhalation of a single dose of 9.1 mg. 
Zdravljenje z zdravilom Adasuve se začne z inhaliranjem enkratnega, 9,1-miligramskega odmerka.
A lower dose of 4.5 mg may be prescribed if the patient did not tolerate the initial dose of 9.1 mg or if a lower dose is considered more appropriate. 
Mogoče je dati nižji, 4,5miligramski odmerek, če bolnik ni dobro prenašal začetnega, 9,1-miligramskega odmerka ali če se zdravnik odloči, da je nižji odmerek primernejši.
What is the risk associated with Adasuve? 
Kakšna tveganja so povezana z zdravilom Adasuve?
Adasuve must not be used in people who are hypersensitive (allergic) to loxapine or any of the other ingredients. 
Zdravila Adasuve ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) loksapin ali katero koli drugo sestavino zdravila.
In studies in agitated patients, bronchospasm was reported as an uncommon but serious adverse reaction, while in subjects with active airways disease, bronchospasm was commonly reported and often required treatment with a short acting beta-agonist. 
V študijah z agitiranimi bolniki so o bronhospazmu poročali kot o občasnem, a resnem neželenem učinku, medtem ko so pri bolnikih z aktivno boleznijo dihalnih poti o bronhospazmu pogosto poročali in je ta večkrat zahteval zdravljenje s kratkotrajno delujočimi agonisti beta.
In the brain, it attaches to and blocks several different receptors on the surface of nerve cells. 
Loksapin deluje tako, da se veže na več različnih receptorjev na površini živčnih celic in blokira njihovo delovanje.
The most common side effects with Adasuve are dysgeusia (taste disturbances), sedation or somnolence (sleepiness) and dizziness. 
Najpogostejši neželeni učinki zdravila Adasuve so bili disgevzija (motnje okušanja), sedacija ali somnolenca (zaspanost) in omotičnost.
The CHMP noted that the administration of Adasuve is non-invasive. 
Odbor CHMP je tudi navedel, da je dajanje zdravila Adasuve neinvazivno.
Adasuve was more effective than placebo at controlling agitation. 
Zdravilo Adasuve je bilo učinkovitejše pri obvladovanju agitacije kot placebo.
Patients should be observed for signs of shortness of breath for one hour after each dose. 
Bolnike je prvo uro po vsakem odmerku treba opazovati za znake kratke sape.
Adasuve loxapine 
Adasuve loksapin
Why has Adasuve been approved? 
Zakaj je bilo zdravilo Adasuve odobreno?
Both studies compared 4.5 mg and 9.1 mg of Adasuve with placebo (a dummy treatment). 
Obe študiji sta primerjali odmerka zdravila Adasuve 4,5 mg in 9,1 mg s placebom (zdravilom brez zdravilne učinkovine).
Adasuve is a medicine that contains the active substance loxapine. 
Adasuve je zdravilo, ki vsebuje zdravilno učinkovino loksapin.
The active substance in Adasuve, loxapine, is an antipsychotic medicine. 
Zdravilna učinkovina v zdravilu Adasuve, loksapin, je antipsihotik.
For the full list of all side effects reported with Adasuve, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Adasuve, glejte navodilo za uporabo.
In the study in patients with schizophrenia, patients taking 4.5 mg of Adasuve had an average fall in PEC score of 8.0 points and patients taking 9.1 mg had an average fall of 8.7 points. 
V študiji pri bolnikih s shizofrenijo so pri bolnikih, ki so prejemali 4,5 mg zdravila Adasuve, zabeležili povprečno znižanje rezultata PEC za 8,0 točk, pri bolnikih, ki so prejemali odmerek 9,1 mg, pa povprečno znižanje za 8,7 točk.
Adasuve is used to rapidly control mild to moderate agitation in adults with schizophrenia or bipolar disorder. 
Zdravilo Adasuve se uporablja za hitro obvladanje blage do zmerne agitacije pri odraslih bolnikih s shizofrenijo ali bipolarno motnjo.
In the study in patients with bipolar disorder, patients taking 4.5 mg of Adasuve had an average fall in PEC score of 8.2 points, and patients taking 9.1 mg had an average fall of 9.2 points. 
V študiji pri bolnikih z bipolarno motnjo so pri bolnikih, ki so prejemali 4,5 mg zdravila Adasuve, zabeležili povprečno znižanje rezultata PEC za 8,2 točke, pri bolnikih, ki so prejemali odmerek 9,1 mg, pa povprečno znižanje za 9,2 točke.
The CHMP concluded that Adasuve has been demonstrated to rapidly control (within minutes) mild to moderate agitation in patients with schizophrenia or bipolar disorder who are cooperative with using an inhaler. 
Odbor CHMP je zaključil, da se je pokazalo, da je mogoče z zdravilom Adasuve hitro obvladati (v nekaj minutah) blago do zmerno agitacijo pri bolnikih s shizofrenijo ali z bipolarno motnjo, ki so pripravljeni uporabiti inhalator.
Information on how to use the inhaler can be found in the package leaflet. 
Za informacije o uporabi inhalatorja glejte navodila za uporabo.
This compared with a fall of 4.7 points in patients taking placebo. 
Pri bolnikih, ki so prejemali placebo, je bila ta vrednost 4,7 točk.
How has Adasuve been studied? 
Kako je bilo zdravilo Adasuve raziskano?
This compared with a fall of 5.8 points in patients taking placebo. 
Pri bolnikih, ki so prejemali placebo, je bila ta vrednost 5,8 točk.
An airway-opening medicine called a short-acting beta agonist should also be available for the treatment of patients who develop bronchospasm (excessive and prolonged contraction of the airway muscles). 
Za zdravljenje bolnikov, pri katerih se razvije bronhospazem (pretirano in dolgotrajno krčenje mišic v dihalnih poteh), mora biti na voljo tudi zdravilo za odpiranje dihalnih poti, imenovano kratkotrajno delujoči agonist beta.
How is Adasuve used? 
Kako se zdravilo Adasuve uporablja?
What is Adasuve used for? 
Za kaj se zdravilo Adasuve uporablja?
What is Adasuve? 
Kaj je zdravilo Adasuve?
How does Adasuve work? 
Kako zdravilo Adasuve deluje?
Conditions or restrictions with regard to the safe and effective use of the medicinal product 
Pogoji in omejitve v zvezi z varno in učinkovito uporabo zdravila
• The risk of bladder cancer risk and relevant risk minimisation advice. 
• Tveganju za raka sečnega mehurja in ustreznim nasvetom za zmanjšanje tega tveganja.
Medical attention may be needed. 
Morda bo potrebna zdravniška pomoč.
These changes are, however, not considered to be clinically relevant. 
Vendar te spremembe ne veljajo za klinično pomembne.
You may have to take this treatment over a long period of time. 
Morda boste morali jemati to zdravilo dolgo časa.
Date of first authorisation: 19 November 2008 Date of latest renewal: 28 November 2013 
Datum prve odobritve: 19. november 2008 Datum zadnjega podaljšanja: 23 julij 2012
Then take your next dose at the usual time. 
Naslednji odmerek vzemite ob običajnem času.
112 tablets. 
112 tablet.
A double dose should not be taken on the same day. 
Na isti dan ne sme vzeti dvojnega odmerka zdravila.
How much to take and when 
Koliko zdravila vzeti in kdaj ga jemati
Your doctor will tell you exactly how many tablets of Jalra to take. 
Zdravnik vam bo natančno povedal, koliko tablet zdravila Jalra morate jemati.
Characteristics in specific groups of patients 
Značilnosti pri specifičnih skupinah bolnikov
• Your doctor will regularly monitor your condition to check that the treatment is having the desired effect. 
- Zdravnik vas bo redno pregledoval in preverjal, ali zdravljenje dosega pričakovan učinek.
Additional information on special populations Elderly (≥ 65 years) 
Drugi podatki o posebnih skupinah bolnikov Starejši bolniki (≥ 65 let)
In the event of an overdose, supportive management is recommended. 
V primeru zaužitja prevelikega odmerka je priporočeno podporno zdravljenje.
Doses higher than 100 mg are not recommended. 
Odmerki nad 100 mg niso priporočljivi.
No data are available (see also section 5.1). 
Podatkov ni na voljo (glejte tudi poglavje 5.1).
The maximum daily dose is 100 mg. 
Najvišji dnevni odmerek je 100 mg.
If you forget to take a dose of this medicine, take it as soon as you remember. 
Če ste pozabili vzeti odmerek tega zdravila, ga vzemite takoj, ko se spomnite.
If you have questions about how long to take this medicine, talk to your doctor. 
Če vas zanima, kako dolgo morate jemati to zdravilo, se pogovorite s svojim zdravnikom.
Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Pogostnosti so definirane kot: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Not all pack sizes may be marketed in your country. 
V vaši državi morda niso na voljo vse velikosti pakiranj.
Since this product has been marketed, the following side effects have also been reported: 
Odkar je zdravilo na trgu, so poročali tudi o naslednjih neželenih učinkih:
Type 2 diabetes develops if the body does not make enough insulin or if the insulin that the body makes does not work as well as it should. 
Sladkorna bolezen tipa 2 se razvije v primeru, ko organizem ne tvori dovolj insulina, ali pa če insulin, ki ga organizem tvori, ne deluje tako, kot bi moral.
EU/1/08/485/001 7 tablets EU/1/08/485/002 14 tablets EU/1/08/485/003 28 tablets EU/1/08/485/004 30 tablets EU/1/08/485/005 56 tablets EU/1/08/485/006 60 tablets EU/1/08/485/007 90 tablets EU/1/08/485/008 112 tablets EU/1/08/485/009 180 tablets EU/1/08/485/010 336 tablets 
EU/1/08/485/001 7 tablet EU/1/08/485/002 14 tablet EU/1/08/485/003 28 tablet EU/1/08/485/004 30 tablet EU/1/08/485/005 56 tablet EU/1/08/485/006 60 tablet EU/1/08/485/007 90 tablet EU/1/08/485/008 112 tablet EU/1/08/485/009 180 tablet EU/1/08/485/010 336 tablet
If you need to see a doctor or go to the hospital, take the pack with you. 
Če morate k zdravniku oziroma v bolnišnico, vzemite škatlo zdravil s seboj.
It is used when diabetes cannot be controlled by diet and exercise alone. 
Uporablja se takrat, ko sladkorne bolezni ni mogoče urediti samo z dieto in telesno vadbo.
EU/1/08/485/011 336 tablets (3 packs of 112) 
EU/1/08/485/011 336 tablet (3 pakiranja po 112 tablet)
What Jalra is and what it is used for 
Kaj je zdravilo Jalra in za kaj ga uporabljamo
The amount of Jalra people have to take varies depending on their condition. 
Koliko zdravila Jalra morajo ljudje jemati, je odvisno od njihovega stanja.
Rare cases of hepatic dysfunction (including hepatitis) have been reported. 
Poročali so o redkih primerih motenega delovanja jeter (vključno s hepatitisom).
Even though you are now starting a medicine for your diabetes, it is important that you continue to follow the diet and/or exercise which has been recommended for you. 
Čeprav boste začeli jemati zdravilo za sladkorno bolezen, je zelo pomembno, da se še naprej držite diete in/ali telesne vadbe, kakor vam priporoča zdravnik.
LAY151 concentrations were approximately 2-3-fold higher than in patients with severe renal impairment. 
Koncentracije presnovka LAY151 so bile približno 2-3-krat višje kot pri bolnikih s hudo okvaro ledvic.
Use of vildagliptin has been associated with a risk of developing acute pancreatitis. 
Uporabo vildagliptina povezujejo s tveganjem za razvoj akutnega pankreatitisa.
There are no adequate data from the use of vildagliptin in pregnant women. 
Ni zadostnih podatkov o uporabi vildagliptina pri nosečnicah.
Multipack: 336 (3 packs of 112) tablets. 
Skupno pakiranje: 336 tablet (3 pakiranja po 112 tablet).
Digoxin (Pgp substrate), warfarin (CYP2C9 substrate) 
Digoksin (substrat P-glikoproteina), varfarin (substrat CYP2C9)
If it is almost time for your next dose, skip the dose you missed. 
Če je že skoraj čas za naslednji odmerek, izpustite pozabljeni odmerek.
Jalra is not a substitute for insulin in insulin-requiring patients. 
Zdravilo Jalra ne more nadomestiti zdravljenja z insulinom pri bolnikih, ki potrebujejo insulin.
If you think you may be allergic to vildagliptin or any of the other ingredients of Jalra, do not take this medicine and talk to your doctor. 
Če menite, da bi lahko bili alergični na vildagliptin ali katerokoli sestavino zdravila Jalra, ne jemljite tega zdravila in se posvetujte z zdravnikom.
Other medicines and Jalra 
Druga zdravila in zdravilo Jalra
The maximum change (increase or decrease) in the exposure to vildagliptin is ~30%, which is not considered to be clinically relevant. 
Največja razlika (povečanje ali zmanjšanje) izpostavljenosti vildagliptinu je bila približno 30 %, kar ocenjujejo za klinično nepomembno.
Jalra should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. 
Zdravila Jalra se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1 ali za zdravljenje diabetične ketoacidoze.
The European Medicines Agency has waived the obligation to submit the results of studies with vildagliptin in all subsets of the paediatric population with type 2 diabetes mellitus (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z vildagliptinom za vse podskupine pediatrične populacije s sladkorno boleznijo tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Pharmacotherapeutic group: Drugs used in diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code: A10BH02 
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, zaviralci dipeptidil peptidaze 4 (DPP4), oznaka ATC: A10BH02
Of these patients, 2,264 patients received vildagliptin as monotherapy and 1,520 patients received vildagliptin in combination with another medicinal product. 
Od teh bolnikov jih je 2.264 prejemalo vildagliptin kot monoterapijo, 1.520 bolnikov pa je prejemalo vildagliptin v kombinaciji z drugim zdravilom.
Insulin is a substance which helps to lower the level of sugar in the blood, especially after meals. 
Insulin je snov, ki pomaga zniževati koncentracijo sladkorja v krvi, posebno po obrokih.
Do not stop taking Jalra unless your doctor tells you to. 
Ne prenehajte jemati zdravila Jalra, če vam tega ne naroči zdravnik.
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults: 
Vildagliptin je indiciran za zdravljenje sladkorne bolezni tipa 2 pri odraslih:
If you have previously taken vildagliptin but had to stop taking it because of liver disease, you should not take this medicine. 
Če ste že jemali vildagliptin, pa ste ga morali prenehati zaradi bolezni jeter, ne smete jemati tega zdravila.
Animal studies have shown excretion of vildagliptin in milk. 
Študije so pokazale, da se pri živalih vildagliptin izloča v mleko.
C] vildagliptin, approximately 85% of the dose was excreted into the urine and 15% of the dose is recovered in the faeces. 
C označenega vildagliptina se je približno 85 % odmerka izločilo z urinom, 15 % odmerka pa so našli v blatu.
What you need to know before you take Jalra 
Kaj morate vedeti, preden boste vzeli zdravilo Jalra
Your doctor will prescribe Jalra either alone or together with certain other antidiabetic medicines which you will already be taking, if these have not proved sufficiently effective to control diabetes. 
Zdravnik vam bo predpisal zdravilo Jalra bodisi za samostojno uporabo ali skupaj z določenimi drugimi zdravili, ki jih že jemljete, če ta zdravila do zdaj niso bila dovolj učinkovita za urejanje sladkorne bolezni.
* p< 0.05 for comparison versus placebo 
* p< 0,05 za primerjavo s placebom
Information on the likely symptoms of overdose was taken from a rising dose tolerability study in healthy subjects given Jalra for 10 days. 
Podatki o verjetnih simptomih prevelikega odmerjanja temeljijo na študiji prenašanja naraščajočih odmerkov, izvedeni na zdravih osebah, ki so prejemale zdravilo Jalra 10 dni.
It is not known if Jalra passes into breast milk. 
Ni znano, ali zdravilo Jalra prehaja v materino mleko.
• Do not use this medicine after the expiry date which is stated on the blister and the carton after 
• Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli poleg oznake “EXP”.
Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes. 
Ker vildagliptin ni niti substrat encimov citokrom P (CYP) 450 niti ne zavira ali inducira encimov CYP 450, ni verjetno, da bi prišlo do interakcij z učinkovinami, ki so substrati, zaviralci ali induktorji teh encimov.
Monotherapy placebo controlled studies 
Študije z monoterapijo, kontrolirane s placebom
Your doctor may wish to alter your dose of Jalra if you are taking other medicines such as: - thiazides or other diuretics (also called water tablets) - corticosteroids(generally used to treat inflammation) - thyroid medicines - certain medicines affecting the nervous system. 
Zdravnik vam bo morda svetoval spremembo odmerka zdravila Jalra, če jemljete druga zdravila kot so: - tiazidi ali drugi diuretiki (imenovani tudi tablete za odvajanje vode) - kortikosteroidi (običajno se jih uporablja za zdravljenje vnetij) - hormoni ščitnice - nekatera zdravila, ki vplivajo na živčevje.
Information regarding overdose with vildagliptin is limited. 
Podatki o prevelikem odmerjanju vildagliptina so omejeni.
How to take Jalra • Swallow the tablets whole with some water. 
Kako jemati zdravilo Jalra - Tablete pogoltnite cele z malo vode.
The active substance of Jalra, vildagliptin, belongs to a group of medicines called “oral antidiabetics”. 
Zdravilna učinkovina zdravila Jalra, vildagliptin, sodi v skupino zdravil, ki se imenujejo “peroralni antidiabetiki”.
The safety and efficacy of Jalra in children and adolescents (< 18 years) have not been established. 
Varnost in učinkovitost zdravila Jalra pri otrocih in mladostnikih (< 18 let) nista bili dokazani.
In vitro data in human kidney microsomes suggest that the kidney may be one of the major organs contributing to the hydrolysis of vildagliptin to its major inactive metabolite, LAY151. 
In vitro podatki, pridobljeni na mikrosomih človeških ledvic, nakazujejo, da bi bile ledvice lahko eden pomembnejših organov za hidrolizo vildagliptina v njegov glavni neaktivni metabolit LAY 151.
Liver enzyme monitoring 
Spremljanje jetrnih encimov
Oral use Jalra can be administered with or without a meal (see also section 5.2). 
Zdravilo Jalra se lahko jemlje z obrokom ali brez njega (glejte tudi poglavje 5.2).
The increased incidence of these tumours in mice is considered not to represent a significant risk to humans based on the lack of genotoxicity of vildagliptin and its principal metabolite, the occurrence of tumours only in one species and the high systemic exposure ratios at which tumours were observed. 
Ocenjeno je, da zvišana incidenca teh tumorjev pri miših ne predstavlja pomembnega tveganja za ljudi glede na to, da vildagliptin in njegov glavni metabolit nista genotoksična, da je do tumorjev prišlo le pri eni živalski vrsti in glede na visoka razmerja med izpostavljenostmi, pri katerih so tumorje opažali.
Excipient with known effect: Each tablet contains 47.82 mg lactose (anhydrous). 
Pomožne snovi z znanim učinkom: Ena tableta vsebuje 47,82 mg laktoze (brezvodne).
No dose adjustments are necessary in elderly patients (see also sections 5.1 and 5.2). 
Za starejše bolnike prilagajanje odmerkov ni potrebno (glejte tudi poglavji 5.1 in 5.2).
There is no experience of vildagliptin use in clinical trials in patients with NYHA functional class IV and therefore use is not recommended in these patients. 
Iz kliničnih preskušanj ni nobenih izkušenj z uporabo vildagliptina pri bolnikih iz funkcijskega razreda IV po klasifikaciji NYHA, zato uporaba pri teh bolnikih ni priporočena.
Limited data from patients with end stage renal disease (ESRD) indicate that vildagliptin exposure is similar to that in patients with severe renal impairment. 
Maloštevilni podatki bolnikov s končno ledvično odpovedjo (ESRD) kažejo, da je pri njih izpostavljenost vildagliptinu podobna kot pri bolnikih s hudo okvaro ledvic.
Three other subjects experienced oedema of the feet, with paraesthesia in two cases. 
Pri treh drugih osebah je prišlo do otekanja stopal, v dveh primerih s parestezijami.
Diabetic skin lesions are a common complication of diabetes. 
Diabetične spremembe na koži so pogost zaplet pri sladkorni bolezni.
7 tablets 14 tablets 28 tablets 30 tablets 56 tablets 60 tablets 90 tablets 112 tablets 180 tablets 336 tablets 
7 tablet 14 tablet 28 tablet 30 tablet 56 tablet 60 tablet 90 tablet 112 tablet 180 tablet 336 tablet
Embryo-foetal toxicity was evaluated in rats and rabbits. 
Toksičnost za zarodek in plod so ocenjevali pri podganah in kuncih.
Vildagliptin was removed by haemodialysis to a limited extent (3% over a 3-4 hour haemodialysis session starting 4 hours post dose). 
Vildagliptin se je s hemodializo izločil le v majhni meri (samo 3 % v 3-4 urah hemodialize z začetkom 4 ure po odmerjanju).